## **Yajing Xing**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8449417/publications.pdf

Version: 2024-02-01

		1478505	1588992	
8	210	6	8	
papers	citations	h-index	g-index	
8	8	8	381	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. Oncotarget, 2015, 6, 15348-15361.	1.8	66
2	Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway. Science China Life Sciences, 2017, 60, 417-428.	4.9	59
3	A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 422.	8.6	23
4	Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of <i>N</i> -Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. Journal of Medicinal Chemistry, 2020, 63, 676-695.	6.4	22
5	The synthesis and antitumor activity of lithocholic acid and its derivatives. Steroids, 2017, 125, 54-60.	1.8	21
6	Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents. ACS Medicinal Chemistry Letters, 2018, 9, 1105-1110.	2.8	11
7	Synthesis and biological evaluation of methylpyrimidine-fused tricyclic diterpene analogs as novel oral anti-late-onset hypogonadism agents. European Journal of Medicinal Chemistry, 2019, 176, 21-40.	5.5	4
8	Synthesis and biological evaluation of 3-nitro-4-chromanone derivatives as potential antiproliferative agents for castration-resistant prostate cancer. RSC Advances, 2019, 9, 33794-33799.	3.6	4